Evidence map›Paper›PMID 27832198›Full record

ArticlePLoS pathogens2016

Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology.

Stanislaw J Gabryszewski, Satish K Dhingra, Jill M Combrinck, Ian A Lewis, Paul S Callaghan, Matthew R Hassett, Amila Siriwardana, Philipp P Henrich, Andrew H Lee, Nina F Gnädig and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Antiplasmodial Activity of 80% Methanolic Extract and Solvent Fractions of Stem Bark ofEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  11. Efficient generation of mNeonGreenFrontiers in cellular and infection microbiology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Methods Used to Investigate theFrontiers in cellular and infection microbiology · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 5 countries.

Stanislaw J GabryszewskiDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.
Satish K DhingraDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.
Jill M CombrinckDivision of Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0003-0936-1761
Ian A LewisDepartment of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.
Paul S CallaghanDepartments of Chemistry and of Biochemistry and Cellular & Molecular Biology, Georgetown University, Washington, DC, United States of America.
Matthew R HassettDepartments of Chemistry and of Biochemistry and Cellular & Molecular Biology, Georgetown University, Washington, DC, United States of America.
Amila SiriwardanaDepartments of Chemistry and of Biochemistry and Cellular & Molecular Biology, Georgetown University, Washington, DC, United States of America.
Philipp P HenrichDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.
Andrew H LeeDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.
Nina F GnädigDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.
Lise MussetLaboratoire de Parasitologie, WHO Collaborating Center for Surveillance of Anti-Malarial Drug Resistance, Institut Pasteur de la Guyane, Cayenne, French Guiana.
Manuel LlinásDepartments of Biochemistry & Molecular Biology and Chemistry, Center for Malaria Research and Center for Infectious Diseases Dynamics, Pennsylvania State University, University Park, Pennsylvania, United States of America.
Timothy J EganDepartment of Chemistry, University of Cape Town, Cape Town, South Africa.
Paul D RoepeDepartments of Chemistry and of Biochemistry and Cellular & Molecular Biology, Georgetown University, Washington, DC, United States of America.
David A FidockDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, New York, United States of America.ORCID http://orcid.org/0000-0001-6753-8938
Columbia University Irving Medical Center · USGeorgetown University · USUniversity of Cape Town · ZAPennsylvania State University · USUniversity of Calgary · CA

Funding

Spatial Patterning During DevelopmentP50GM071508 · NIGMS · PRINCETON UNIVERSITY · PI POWELL, SUSAN M · 2004 to 2013
$30.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007367 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI REINER, STEVEN L · 1985 to 2021
$25.1M
Role of pfcrt in chloroquine resistance in P. falciparumR01AI050234 · NIAID · YESHIVA UNIVERSITY · PI FIDOCK, DAVID A · 2001 to 2015
$5.7M
Defining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug ResistanceR37AI050234 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2018 to 2026
$4.4M
Defining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4M
Novel antimalarial strategies using metabolomic network discoveryDP2OD001315 · OD · PRINCETON UNIVERSITY · PI LLINAS, MANUEL · 2007 to 2007
$2.4M
Columbia University Graduate Training Program in Microbiology and ImmunologyT32AI106711 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Nicholas Arpaia, Uttiya Basu · 2014 to 2026
$2.1M
Plasmodium heme detoxification probesR01AI110329 · NIAID · UNIVERSITY OF CAPE TOWN · PI EGAN, TIMOTHY JOHN · 2014 to 2018
$668k
Dissecting the molecular basis of PfCRT-mediated antimalarial drug resistanceF30AI114070 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GABRYSZEWSKI, STANISLAW J · 2015 to 2017
$122k
NIAID NIH HHS F30 AI114070NIAID NIH HHS R01 AI050234NIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI110329NIAID NIH HHS R37 AI050234NIAID NIH HHS T32 AI106711NIGMS NIH HHS P50 GM071508NIGMS NIH HHS T32 GM007367NIH HHS DP2 OD001315
6 · The paper itself

Abstract

Southeast Asia is an epicenter of multidrug-resistant Plasmodium falciparum strains. Selective pressures on the subcontinent have recurrently produced several allelic variants of parasite drug resistance genes, including the P. falciparum chloroquine resistance transporter (pfcrt). Despite significant reductions in the deployment of the 4-aminoquinoline drug chloroquine (CQ), which selected for the mutant pfcrt alleles that halted CQ efficacy decades ago, the parasite pfcrt locus is continuously evolving. This is highlighted by the presence of a highly mutated allele, Cam734 pfcrt, which has acquired the singular ability to confer parasite CQ resistance without an associated fitness cost. Here, we used pfcrt-specific zinc-finger nucleases to genetically dissect this allele in the pathogenic setting of asexual blood-stage infection. Comparative analysis of drug resistance and growth profiles of recombinant parasites that express Cam734 or variants thereof, Dd2 (the most common Southeast Asian variant), or wild-type pfcrt, revealed previously unknown roles for PfCRT mutations in modulating parasite susceptibility to multiple antimalarial agents. These results were generated in the GC03 strain, used in multiple earlier pfcrt studies, and might differ in natural isolates harboring this allele. Results presented herein show that Cam734-mediated CQ resistance is dependent on the rare A144F mutation that has not been observed beyond Southeast Asia, and reveal distinct impacts of this and other Cam734-specific mutations on CQ resistance and parasite growth rates. Biochemical assays revealed a broad impact of mutant PfCRT isoforms on parasite metabolism, including nucleoside triphosphate levels, hemoglobin catabolism and disposition of heme, as well as digestive vacuole volume and pH. Results from our study provide new insights into the complex molecular basis and physiological impact of PfCRT-mediated antimalarial drug resistance, and inform ongoing efforts to characterize novel pfcrt alleles that can undermine the efficacy of first-line antimalarial drug regimens.

Indexed as

AminoquinolinesAntimalarialsDrug ResistanceGenetic FitnessGenotypeHumansMalaria, FalciparumMass SpectrometryMembrane Transport ProteinsMicrobial Sensitivity TestsMutationPlasmodium falciparumProtozoan ProteinsVacuoles4-aminoquinolineAminoquinolinesAntimalarialsMembrane Transport ProteinsPfCRT protein, Plasmodium falciparumProtozoan Proteins

Identifiers

PMID27832198
PMCPMC5104409
OpenAlexW2553625841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.